Literature DB >> 21416584

Plerixafor plus granulocyte-colony stimulating factor for autologous hematopoietic stem cell mobilization in patients with metastatic neuroblastoma.

Shakeel Modak1, Irene Y Cheung, Brian H Kushner, Kim Kramer, Lilian Reich, Nai-Kong V Cheung.   

Abstract

Current therapies for high-risk neuroblastoma (NB) necessitate the availability of several aliquots of autologous peripheral blood stem cells to reverse-associated myelosuppression. Priming with the CXCR4 inhibitor plerixafor plus G-CSF was associated with successful stem cell harvest in 5/7 heavily prior-treated patients with stage 4 NB who had previously failed G-CSF priming. Minimal residual disease was not detected in harvested cells from any patient despite the presence of disease in bone/bone marrow in 6/7. Hematopoietic reconstitution was achieved in all three patients receiving plerixafor-primed stem cells after myeloablative therapy. Plerixafor is an effective and safe agent for stem cell collection in patients with NB.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21416584     DOI： 10.1002/pbc.23132

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  6 in total

1.  Efficacy of plerixafor in children with malignant tumors failing to mobilize a sufficient number of hematopoietic progenitors with G-CSF.

Authors:  A A Maschan; D N Balashov; E E Kurnikova; P E Trakhtman; E V Boyakova; E V Skorobogatova; G A Novichkova; M A Maschan
Journal:  Bone Marrow Transplant       Date:  2015-04-27       Impact factor: 5.483

2.  β-Arrestin1 and distinct CXCR4 structures are required for stromal derived factor-1 to downregulate CXCR4 cell-surface levels in neuroblastoma.

Authors:  Ian C Clift; Adebowale O Bamidele; Christie Rodriguez-Ramirez; Kimberly N Kremer; Karen E Hedin
Journal:  Mol Pharmacol       Date:  2014-01-22       Impact factor: 4.436

3.  Successful mobilization using a combination of plerixafor and G-CSF in pediatric patients who failed previous chemomobilization with G-CSF alone and possible complications of the treatment.

Authors:  Kyung Taek Hong; Hyoung Jin Kang; Nam Hee Kim; Min Sun Kim; Ji Won Lee; Hyery Kim; Kyung Duk Park; Hee Young Shin; Hyo Seop Ahn
Journal:  J Hematol Oncol       Date:  2012-03-30       Impact factor: 17.388

Review 4.  Targeting the Tumor Microenvironment in Neuroblastoma: Recent Advances and Future Directions.

Authors:  Shweta Joshi
Journal:  Cancers (Basel)       Date:  2020-07-25       Impact factor: 6.639

5.  The Biological and Clinical Relevance of G Protein-Coupled Receptors to the Outcomes of Hematopoietic Stem Cell Transplantation: A Systematized Review.

Authors:  Hadrien Golay; Simona Jurkovic Mlakar; Vid Mlakar; Tiago Nava; Marc Ansari
Journal:  Int J Mol Sci       Date:  2019-08-09       Impact factor: 5.923

Review 6.  The Potential of Mesenchymal Stromal Cells in Neuroblastoma Therapy for Delivery of Anti-Cancer Agents and Hematopoietic Recovery.

Authors:  Caroline Hochheuser; Nina Y Kunze; Godelieve A M Tytgat; Carlijn Voermans; Ilse Timmerman
Journal:  J Pers Med       Date:  2021-02-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.